The aim of the study is to evaluate the efficacy of Disci/Rhus toxicodendron. comp.® in patients with chronic low back pain compared to waiting list group, or placebo.
Inclusion Criteria: * Male and female patients, 30 to 75 years * Willingness of following the study protocol * Clinical diagnosis of chronic low back pain * Low back pain since at least 3 months * Average pain intensity of at least 40 mm on VAS (0-100 mm) in the last 7 days * In the last 4 weeks only oral NSAD and muscle relaxation treatment * Effective oral contraception in woman * Informed consent Exclusion Criteria: * Previous treatment with DISCI comp. * Treatment with other than NSAID * Routine use of pain drugs for other diseases * Protrusio or prolapse of one or more intervertebral discs with neurological symptoms * Previous spine surgery * (Suspicious) infectious spondylopathy * Low back pain because of malignant or infectious disease * Other causes of back pain symptoms (e.g. M. Bechterev, M. Reiter) * Congenital deformity of spine (without minor lordosis or kyphosis or scoliosis * (Suspicious) osteoporosis with compression fracture * (Suspicious) spinal stenosis * Spondylolysis or spondylolisthesis * Physiotherapy in the last four weeks or planed during trial * Begin of a new treatment for low back pain * Complementary treatment in the last four weeks or planed during trial * Patients who are not able to cooperate in a sufficient way * Patients with alcohol or substance abuse * Participation in another clinical trial * Severe chronical or acute disease which does not allow study participation * Patients with bleeding disorders or oral anticoagulation treatment * Pregnancy and breast feeding * Patients with application for pension * Patients involved in planning or coordination of the study * Hypersensitivity against drug components